The merger of the four legacy pediatric cooperative groups to form the Children?s Oncology Group (COG) presents a unique opportunity to serve all children in North America. Our goals are to expand access to innovative clinical and translational research for cancer treatment, prevention and control and to increase the level of participation by CCOPs/MBCCOPs in the mission of the COG. This application supports the COG as a treatment and prevention/control Community Clinical Oncology Program (CCOP) Research Base. The COG will make available to CCOPs/MBCCOPs current treatment protocols with access to investigational agents and special centralized reference laboratories, thus promoting high quality cancer care for children treated in community settings. A high priority has been placed on developing protocols that can be feasibly performed in smaller COG institutions, which include most of our affiliated CCOPs. COG will encourage CCOP investigators to participate in all aspects of the Group?s scientific mission in addition to enrolling patients on study. The COG will provide continuing training and support for CCOP institutional personnel including clinical research associates and oncology nurses, and will ensure that all CCOPs maintain high quality assurance standards for membership, accrual, and institutional performance. The Cancer Control Committee (CCC) administers the COG cancer prevention and control research program. Its mission is to improve the quality of care and survivorship for children with cancer, to ensure access to state-of-the-art cancer therapy for traditionally underserved groups (including minority and adolescent/young adult populations), and to develop hypothesis-driven prevention and control research for children. The membership of the CCC is diverse and includes the clinical disciplines of hematology/oncology, surgery, radiation therapy, oncology nursing, and other physician specialists for infectious diseases, pediatric cardiology and pulmonology; public health disciplines including epidemiology, health services research, and biostatistics; and behavioral researchers in psychology, sociology and social work. COG cancer control research includes assessment of alternate trial endpoints such as health-related quality-of-life and economic measures; the identification and prevention of treatment-related sequelae; symptom management, pain control and supportive care; and community oncology and outreach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA095861-04
Application #
6950422
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
O'Mara, Ann M
Project Start
2002-09-20
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
4
Fiscal Year
2005
Total Cost
$1,572,514
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Dupuis, L Lee; Kelly, Kara M; Krischer, Jeffrey P et al. (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer 124:1188-1196
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579
Alexander, Sarah; Fisher, Brian T; Gaur, Aditya H et al. (2018) Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 320:995-1004
Knight, Kristin R; Chen, Lu; Freyer, David et al. (2017) Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 35:440-445
Haase, Joan E; Kintner, Eileen K; Robb, Sheri L et al. (2017) The Resilience in Illness Model Part 2: Confirmatory Evaluation in Adolescents and Young Adults With Cancer. Cancer Nurs 40:454-463
Freyer, David R; Chen, Lu; Krailo, Mark D et al. (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63-74
Viola, Adrienne; Balsamo, Lyn; Neglia, Joseph P et al. (2017) The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. J Pediatr Hematol Oncol 39:174-178
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Landier, Wendy; Chen, Yanjun; Hageman, Lindsey et al. (2017) Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129:1919-1926
Roth, Michael E; O'Mara, Ann M; Seibel, Nita L et al. (2016) Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. J Oncol Pract 12:e388-95

Showing the most recent 10 out of 66 publications